Loading...

Neil Mehta, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Phone415-502-2569
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoM.D.2006 Medicine

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. Hepatocellular carcinoma (HCC) patients listed in short wait regions remain advantaged for liver transplant (LT) following 2015 HCC policy change. Liver Transpl. 2019 Dec 13. PMID: 31833634.
      View in: PubMed
    2. Cullaro G, Rubin JB, Mehta N, Lai JC. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Liver Transpl. 2019 Oct 14. PMID: 31610089.
      View in: PubMed
    3. Mehta N, Dodge JL, Yao FY. REPLY. Hepatology. 2019 Oct; 70(4):1491-1492. PMID: 31095762.
      View in: PubMed
    4. Lee E, Sarkar M, Dodge J, Kohi M, Mehta N. Shorter Height is Associated with Lower Probability of Liver Transplantation in Patients with Hepatocellular Carcinoma. Transplantation. 2019 Sep 30. PMID: 31577670.
      View in: PubMed
    5. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 Aug 02; 2(8):e1910326. PMID: 31469395.
      View in: PubMed
    6. Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study. Prehosp Disaster Med. 2019 Aug; 34(4):393-400. PMID: 31389323.
      View in: PubMed
    7. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2. PMID: 31374215.
      View in: PubMed
    8. Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette CT, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019 Jul 26. PMID: 31357028.
      View in: PubMed
    9. Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology. 2019 Jul 25. PMID: 31344273.
      View in: PubMed
    10. Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 Oct; 70(4):1185-1196. PMID: 30779440.
      View in: PubMed
    11. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 Aug; 19(8):2210-2218. PMID: 30861298.
      View in: PubMed
    12. Brian Lee, Mary Rinella, Gene Im, John Rice, Oren Fix, George Therapondos, Hyosun Han, David Victor, Ethan Weinberg, Cristine Hsu, Michael Voigt, Haripriya Maddur, Sheila Eswaran, David Foley, R. Mark Ghobrial, Lisanne Dinges, Jennifer Dodge, Neil Mehta, Michael R. Lucey, Norah Terrault. PS-206-Patterns and predictors of alcohol use after early liver transplant for alcoholic hepatitis. Journal of Hepatology. 2019 Apr 1; 70(1):e137.
      View in: Publisher Site
    13. Subramanian A, Connor DM, Berger G, Lessing JN, Mehta N, Manesh R, Kohlwes J. A Curriculum for Diagnostic Reasoning: JGIM's Exercises in Clinical Reasoning. J Gen Intern Med. 2019 Mar; 34(3):344-345. PMID: 30334181.
      View in: PubMed
    14. Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25. PMID: 31168361.
      View in: PubMed
    15. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 Mar; 69(3):1193-1205. PMID: 30548884.
      View in: PubMed
    16. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 02; 25(2):228-241. PMID: 30198150.
      View in: PubMed
    17. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 02; 25(2):207-216. PMID: 30246323.
      View in: PubMed
    18. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1. PMID: 30660729.
      View in: PubMed
    19. Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217. PMID: 30543796.
      View in: PubMed
    20. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2019 06; 21(6):731-738. PMID: 30391218.
      View in: PubMed
    21. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 10; 24(10):1346-1356. PMID: 30067889.
      View in: PubMed
    22. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl. 2018 09; 24(9):1171-1177. PMID: 29781162.
      View in: PubMed
    23. Roberts DE, Kakar S, Mehta N, Gill RM. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence. Am J Surg Pathol. 2018 07; 42(7):855-865. PMID: 29649017.
      View in: PubMed
    24. Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes. Transplant Direct. 2018 Jul; 4(7):e363. PMID: 30046653.
      View in: PubMed
    25. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018 08; 68(2):449-461. PMID: 29476694.
      View in: PubMed
    26. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 05; 102(5):816-822. PMID: 29505494.
      View in: PubMed
    27. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1. PMID: 29655837.
      View in: PubMed
    28. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018 04; 102(4):640-647. PMID: 29319620.
      View in: PubMed
    29. M. Kohi, M. Sarka, J. Dodge, J. Roberts, N. Terrault, N. Mehta. Abstract No. 525 Liver transplantation rates for hepatocellular carcinoma: is there a sex-related difference?. Journal of Vascular and Interventional Radiology. 2018 Apr 1; 29(4):s221.
      View in: Publisher Site
    30. B. Lee, G. Im, J. Dodge, M. Voigt, J. Rice, M.R. Lucey, D. Foley, L. Platt, A. Gurakar, N. Mehta, G. Therapondos, H. Han, D. Victor, O. Fix, L. Dinges, D. Dronamraju, C. Hsu, M. Rinella, H. Maddur, S. Eswaran, J. Hause, R.M. Ghobrial, Z. Li, N. Terrault. SAT-448 Higher early post-liver transplant mortality in recipients with severe alcoholic hepatitis versus alcoholic cirrhosis. Journal of Hepatology. 2018 Apr 1; 68:s808.
      View in: Publisher Site
    31. E. Phillips, R. Kohlbrenner, A. True-Yasaki, N. Fidelman, A. Taylor, E. Lehrman, M. Kohi, K. Kolli, R. Kerlan, N. Mehta. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection. Journal of Vascular and Interventional Radiology. 2018 Apr 1; 29(4):s220.
      View in: Publisher Site
    32. Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 03; 24(3):327-329. PMID: 29351366.
      View in: PubMed
    33. Azeem N, Ajmera V, Hameed B, Mehta N. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels. Hepatol Commun. 2018 04; 2(4):349-353. PMID: 29619414.
      View in: PubMed
    34. Mehta NJ, Latoures R, Stechert MM, Fidler RL, Hirsch J. Interventions to improve the mechanical ventilation fidelity of the Laerdal SimMan® 3G simulation mannequin. Can J Anaesth. 2018 05; 65(5):600-602. PMID: 29243162.
      View in: PubMed
    35. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018 05; 18(5):1206-1213. PMID: 29068145.
      View in: PubMed
    36. Mehta N, Yao FY. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl. 2017 12; 23(12):1596-1600. PMID: 29024442.
      View in: PubMed
    37. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018 06; 16(6):955-964. PMID: 29175528.
      View in: PubMed
    38. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant. 2017 Nov; 31(11). PMID: 28881064.
      View in: PubMed
    39. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 09; 101(9):2071-2078. PMID: 28353492.
      View in: PubMed
    40. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. PMID: 28340509.
      View in: PubMed
    41. Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368. PMID: 28626784.
      View in: PubMed
    42. Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation. 2017 05; 101(5):1001-1008. PMID: 27926593.
      View in: PubMed
    43. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500. PMID: 27838698.
      View in: PubMed
    44. Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun. 2017 02; 1(1):18-22. PMID: 29404430.
      View in: PubMed
    45. Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 12; 151(6):1062-1065. PMID: 27983951.
      View in: PubMed
    46. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 10; 64(4):1178-88. PMID: 27481548.
      View in: PubMed
    47. Mehta N, Yao FY. Reply. Liver Transpl. 2016 08; 22(8):1164-5. PMID: 27097078.
      View in: PubMed
    48. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9. PMID: 27236153.
      View in: PubMed
    49. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul - Aug; 15(4):545-549. PMID: 31227113.
      View in: PubMed
    50. Mehta N, Roberts JP, Yao FY. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4. PMID: 26951991.
      View in: PubMed
    51. Lê-Scherban F, Albrecht SS, Bertoni A, Kandula N, Mehta N, Diez Roux AV. Immigrant status and cardiovascular risk over time: results from the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2016 06; 26(6):429-435.e1. PMID: 27221804.
      View in: PubMed
    52. G. Sapisochin, N. Mehta, I. Scalera, C. Sposito, F.Y. Yao, P. Muiesan, V. Mazzaferro, D.R. Grant. HCC recurrence following liver tranplantation should be aggresively treated to increase patient survival. Hepato Pancreato Biliary. 2016 Apr 1; 18:e197.
      View in: Publisher Site
    53. G. Sapisochin, M. Facciuto, N. Mehta, E. Vibert, R. Hernandez-Alejandro, A.D. Pinna, S. Hwang, V.G. Agopian, G. Gores, J. Reyes, O. Soubrane, T. Reichman, P. Kim, C. Sposito, P.A. Clavien, C. Toso, N. Kneteman, J. Bruix. “Very early” intrahepatic cholangiocarcinoma may become an acceptable indication for liver transplantation. A multicenter validation study. Hepato Pancreato Biliary. 2016 Apr 1; 18:e46-e47.
      View in: Publisher Site
    54. Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Curr Opin Organ Transplant. 2016 Apr; 21(2):91-8. PMID: 26807513.
      View in: PubMed
    55. Mehta N, Yao FY. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology. 2016 May; 63(5):1415-7. PMID: 26679367.
      View in: PubMed
    56. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016 Feb; 22(2):178-87. PMID: 26479422.
      View in: PubMed
    57. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4. PMID: 26718172.
      View in: PubMed
    58. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77. PMID: 25689978.
      View in: PubMed
    59. Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant. 2015 Jan; 29(1):52-9. PMID: 25366656.
      View in: PubMed
    60. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8. PMID: 25045002.
      View in: PubMed
    61. Yao FY, Hameed B, Mehta N, Roberts JP. Response to letter to the editors. Liver Transpl. 2014 Oct; 20(10):1285. PMID: 25155484.
      View in: PubMed
    62. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014 Aug; 20(8):945-51. PMID: 24797281.
      View in: PubMed
    63. M. Samoylova, J. Dodge, F. Yao, N. Mehta, J. Roberts. Should Hepatocellular Carcinoma Patients With Multiple Tumors <2cm Be Transplanted?. Transplantation Journal. 2014 Jul 1; 98:698.
      View in: Publisher Site
    64. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8. PMID: 24493311.
      View in: PubMed
    65. Srinivasan M, Mehta N. BMJ endgames: a new web-based BMJ/JGIM collaboration. J Gen Intern Med. 2014 Mar; 29(3):423-4. PMID: 24395105.
      View in: PubMed
    66. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013 Dec; 19(12):1343-53. PMID: 24285611.
      View in: PubMed
    67. Mendelsohn BA, Mehta N, Hameed B, Pekmezci M, Packman S, Ralph J. Adult-Onset Fatal Neurohepatopathy in a Woman Caused by MPV17 Mutation. JIMD Rep. 2014; 13:37-41. PMID: 24190800.
      View in: PubMed
    68. Mehta N, Yao FY. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013 Oct; 19(10):1055-8. PMID: 23959652.
      View in: PubMed
    69. Yao F, Mehta N. Reply: To PMID 23333661. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1674. PMID: 24035772.
      View in: PubMed
    70. Mehta N, Hirose R. Immunosuppression: Conventions and controversies. Clin Liver Dis (Hoboken). 2013 Aug; 2(4):188-191. PMID: 30992859.
      View in: PubMed
    71. Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013 May; 11(5):572-8. PMID: 23333661.
      View in: PubMed
    72. Neil Mehta, Aparna Goel, Karen C. Bagatelos, James L. Buxbaum, Nicholas Fidelman, John P. Roberts, Norah A. Terrault, Francis Yao, James W. Ostroff. 1016 Risk of Hepatic Artery and Biliary Complications in Liver Transplant Recipients Treated With Transarterial Chemoembolization. Gastroenterology. 2012 May 1; 142(5):s-939-s-940.
      View in: Publisher Site
    Neil's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (141) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (38) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑